KYRN.F Stock Overview
Through its subsidiaries, researches and develops, manufactures, and sells ethical and generic drugs in Japan and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 5/6 |
| Dividends | 2/6 |
My Notes
Capture your thoughts, links and company narrative
KYORIN Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥10.00 |
| 52 Week High | JP¥10.00 |
| 52 Week Low | JP¥10.00 |
| Beta | -0.097 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 0% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
| KYRN.F | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0% | -0.3% | -2.7% |
| 1Y | n/a | 7.9% | 23.4% |
Return vs Industry: Insufficient data to determine how KYRN.F performed against the US Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how KYRN.F performed against the US Market.
Price Volatility
| KYRN.F volatility | |
|---|---|
| KYRN.F Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 10.6% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.9% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: KYRN.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine KYRN.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1923 | 2,042 | Yutaka Ogihara | www.kyorin-pharm.co.jp |
KYORIN Pharmaceutical Co., Ltd., through its subsidiaries, researches and develops, manufactures, and sells ethical and generic drugs in Japan and internationally. The company offers Flutiform, a drug for the treatment of asthma; Lyfuna for cough treatment; Desalex, an antiallergic agent; Beova, Uritos, and Imidafenacin KYORIN therapeutic agents for overactive bladder; Lasvic, a quinolone synthetic antibacterial agent; Pentasa, a remedy for ulcerative colitis/Crohn's disease; Nasonex and Mometasone KYORIN, which are used as allergic rhinitis therapeutic agents; and Kipres, a leukotriene receptor antagonist anti-bronchial asthma and allergic rhinitis drug. It also provides Mucodyne, a mucoregulating drug; Montelukast KM, a drug for the treatment of bronchial asthma and allergic rhinitis; GeneSoC, a real-time PCR system; Rubysta, a disinfectant cleaner; Milton, a disinfectant; over-the-counter drugs; prescription medicines and quasi-drugs, diagnostics, and industrial chemicals; and reagents, intermediates, and other products.
KYORIN Pharmaceutical Co., Ltd. Fundamentals Summary
| KYRN.F fundamental statistics | |
|---|---|
| Market cap | US$531.65m |
| Earnings (TTM) | US$30.83m |
| Revenue (TTM) | US$765.76m |
17.2x
P/E Ratio0.7x
P/S RatioIs KYRN.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| KYRN.F income statement (TTM) | |
|---|---|
| Revenue | JP¥119.73b |
| Cost of Revenue | JP¥68.41b |
| Gross Profit | JP¥51.33b |
| Other Expenses | JP¥46.51b |
| Earnings | JP¥4.82b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 05, 2025
| Earnings per share (EPS) | 83.90 |
| Gross Margin | 42.87% |
| Net Profit Margin | 4.03% |
| Debt/Equity Ratio | 18.9% |
How did KYRN.F perform over the long term?
See historical performance and comparisonDividends
3.6%
Current Dividend Yield38%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 06:40 |
| End of Day Share Price | 2024/10/23 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
KYORIN Pharmaceutical Co., Ltd. is covered by 8 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ritsuo Watanabe | BofA Global Research |
| Hidemaru Yamaguchi | Citigroup Global Markets Japan Inc. |
| Hidemaru Yamaguchi | Citigroup Inc |